# 2026-09366: FDA Crowdsources Drug Reuse Ideas for Rare Disease Fixes

2026-09366, Drug Repurposing for Unmet Medical Needs; Request for Information, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-12, effective Submit either electronic or written comments, data, or information by June 11, 2026. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09366
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09366
- Title: Drug Repurposing for Unmet Medical Needs; Request for Information
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 25897
- Published: 2026-05-12
- Effective: Submit either electronic or written comments, data, or information by June 11, 2026.
- Comments close: 2026-06-11
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Crowdsources Drug Reuse Ideas for Rare Disease Fixes

## Summary

The FDA wants your ideas on how to reuse existing drugs to treat diseases that don’t have good options yet. They’re especially interested in drugs that companies aren’t currently trying to repurpose. If you have suggestions, send them by June 11, 2026, to help the FDA focus on the most promising treatments and speed up new uses without extra costs.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is opening a public docket to solicit input and comments on FDA's efforts with respect to drug repurposing to address unmet medical needs. FDA is requesting information on potential priority disease areas and potential candidates for drug repurposing, with a focus on FDA-approved drugs for which there appears to be no commercial interest in adding a new use through a supplement to a new drug application (supplemental application). Information provided through this public docket will help the Agency refine our efforts toward considering and evaluating candidates for drug repurposing.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-09366 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/12/2026-09366/drug-repurposing-for-unmet-medical-needs-request-for-information)
- [2026-09366 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-12/pdf/2026-09366.pdf)

## Related
- [Previous: 2026-09365, Self-Regulatory Organizations; BOX Exchange LLC; Notice of Filing and Immediate…](https://policyrisk.com/federal-register/2026-09365)
- [Next: 2026-09367, Notice of Formal Determination on Records Release](https://policyrisk.com/federal-register/2026-09367)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09366 (as of 2026-06-08).
